Omidenepag isopropyl

Omidenepag isopropyl
Clinical data
Trade names	Eybelis
Other names	DE-117
Identifiers
	IUPAC name Propan-2-yl 2-[[6-[[(4-pyrazol-1-ylphenyl)methyl-pyridin-3-ylsulfonylamino]methyl]pyridin-2-yl]amino]acetate;
CAS Number	1187451-19-9;
PubChem CID	44230999;
DrugBank	DB15071;
UNII	G0G0H52U6K;
KEGG	D10966;
Chemical and physical data
Formula	C26H28N6O4S
Molar mass	520.61 g·mol−1

Omidenepag isopropyl (INN; trade name Eybelis) is a pharmaceutical drug used for the treatment of glaucoma and ocular hypertension.

Medical uses

Omidenepag isopropyl as a 0.002% ophthalmic solution was approved in Japan in 2018 for the treatment of glaucoma and ocular hypertension.[1] It is being evaluated in the United States and Singapore for the same indications.[1]

Adverse effects

The most common adverse effects of omidenepag isopropyl are conjunctival hyperemia and macular edema, including cystoid macular edema.[1]

Pharmacology

Chemical structure of omidenepag, the active metabolite of omidenepag isopropyl

Omidenepag isopropyl is a prodrug that is converted by hydrolysis of its isopropyl ester to the active metabolite omidenepag.[2] Omidenepag is a selective prostaglandin E2 receptor agonist.[3][4]

History

Omidenepag isopropyl was developed by Ube Industries and Santen Pharmaceutical.[1]

References

Duggan S (December 2018). "Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval". Drugs. 78 (18): 1925–1929. doi:10.1007/s40265-018-1016-1. PMID 30465134. S2CID 53721056.
"Omidenepag isopropyl". DrugCentral. Division of Translational Informatics at University of New Mexico.
Kirihara T, Taniguchi T, Yamamura K, Iwamura R, Yoneda K, Odani-Kawabata N, et al. (January 2018). "Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent". Investigative Ophthalmology & Visual Science. 59 (1): 145–153. doi:10.1167/iovs.17-22745. PMID 29332128.
Ida Y, Hikage F, Umetsu A, Ida H, Ohguro H (September 2020). "Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells". Scientific Reports. 10 (1): 16018. Bibcode:2020NatSR..1016018I. doi:10.1038/s41598-020-72538-x. PMC 7524797. PMID 32994409.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[Duggan-1] Duggan S (December 2018). "Omidenepag Isopropyl Ophthalmic Solution 0.002%: First Global Approval". Drugs. 78 (18): 1925–1929. doi:10.1007/s40265-018-1016-1. PMID 30465134. S2CID 53721056.

[2] "Omidenepag isopropyl". DrugCentral. Division of Translational Informatics at University of New Mexico.

[3] Kirihara T, Taniguchi T, Yamamura K, Iwamura R, Yoneda K, Odani-Kawabata N, et al. (January 2018). "Pharmacologic Characterization of Omidenepag Isopropyl, a Novel Selective EP2 Receptor Agonist, as an Ocular Hypotensive Agent". Investigative Ophthalmology & Visual Science. 59 (1): 145–153. doi:10.1167/iovs.17-22745. PMID 29332128.

[4] Ida Y, Hikage F, Umetsu A, Ida H, Ohguro H (September 2020). "Omidenepag, a non-prostanoid EP2 receptor agonist, induces enlargement of the 3D organoid of 3T3-L1 cells". Scientific Reports. 10 (1): 16018. Bibcode:2020NatSR..1016018I. doi:10.1038/s41598-020-72538-x. PMC 7524797. PMID 32994409.